Latest Health News

Sparc Technologies progresses its pioneering green hydrogen pilot plant and graphene-based coatings, backed by a significant government grant and a successful capital raise.

The Environmental Group Limited (ASX – EGL) has landed a $1.9 million contract to design and build its inaugural PFAS treatment plant, marking a key milestone in commercialising its proprietary environmental technology.

Vitasora Health has completed the first tranche of its $11 million capital raise, positioning the company to fund growth initiatives and reach cash flow breakeven in the second half of fiscal 2026.

Manuka Resources Ltd has been reinstated to ASX trading following the announcement of a proposed material capital raising, signaling renewed investor interest.

Resonance Health is expanding its clinical trial operations with a third TrialsWest site in Mandurah, WA, set to open in August 2025, enhancing participant recruitment and supporting ongoing pharmaceutical trials.

Argent BioPharma has begun supplying its EU-GMP cannabinoid API for drug-resistant epilepsy treatment at University Medical Centre Ljubljana, marking a key clinical and regulatory milestone in Europe.

BlinkLab has expanded its pivotal FDA autism diagnostic trial by adding the University of Nebraska Medical Center as a second U.S. clinical site, advancing toward broader validation and regulatory clearance.

Beetaloo Energy has completed the longest hydraulic stimulation in the Beetaloo Basin at its Carpentaria-5H well, paving the way for upcoming flow testing and potential production milestones.

SDI Limited reports a flat sales performance for FY25 with regional growth offset by declines in key markets, while advancing its Montrose facility project with funding plans underway.

MedAdvisor Limited has finalized the sale of its Australian and New Zealand operations to Jonas Software for an estimated $42.35 million, marking a strategic pivot towards its US business. The company also announced upcoming CFO changes as it refocuses its growth trajectory.

ECS Botanics is supplying its Avani THC10 capsules to a University of Western Australia clinical trial exploring medicinal cannabis as a treatment for obstructive sleep apnoea. The study aims to shed light on THC’s impact on sleep quality and cognitive function.

EVE Health Group has placed its first commercial purchase order for Dyspro™, a cannabinoid-based pharmaceutical targeting painful menstruation, signaling a key step toward market entry. The product is set for manufacturing and distribution within weeks, tapping into a rapidly growing global women’s health market.